Skip to main content

Table 1 Clinical and experimental therapeutic strategies for EBV-induced cancer

From: Signaling pathways of EBV-induced oncogenesis

Therapy/drug Target Function Cancer/disease References
CTL LMP1/LMP2 Stimulates LMP-specific T cell expansion NK/T cell lymphoma [82,83,84]
TCR EBNA1/LMP1/
LMP2A
Stimulate and expand EBV-specific CD8 + T cells in patients Progressive multiple sclerosis [85]
Recombinant vaccinia virus ENBA1/LMP2 Promote the production of EBNA1/LMP2 antibodies Nasopharyngeal carcinoma [87]
DNAzyme LMP1 Targeted degradation of LMP1 mRNA Nasopharyngeal carcinoma [88]
Fedratinib, AZD1480 and LY294002 JAK2, PI3K and mTOR Inhibit the expression of PD-L1 and restore immune surveillance Gastric cancer [89]
IMD-0354 NF-κB Inhibit proliferation and increase apoptosis NK/T cell lymphoma [90]
AT13387 Hsp90 Inhibit the expression of AKT/p-AKT, restore the function of p27 and inhibit cancer cell proliferation Nasopharyngeal carcinoma [92]